

Liposarcoma - Pipeline Insight, 2021

<https://marketpublishers.com/r/L8CD12402EFEN.html>

Date: October 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: L8CD12402EFEN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Liposarcoma - Pipeline Insight, 2021," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Liposarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Liposarcoma Understanding

Liposarcoma: Overview

Liposarcomas are rare type of malignant tumors of fatty tissue. They are the second most common type of soft-tissue sarcoma. Liposarcoma can occur in fat cells in any part of the body, but most cases occur in the muscles of the limbs or in the abdomen. Liposarcomas are typically found in adults, typically between the ages of 40 and 60, and are rare in children. Liposarcoma occurs more often in men than women. Liposarcoma risk factors may include radiation, family cancer syndromes, a damaged lymph system, and/or exposure to certain chemicals. Liposarcoma stages describe the extent of tumor spread with stage IV representing the most extensive cancer with metastatic spread. Liposarcoma can be diagnosed by imaging the body by X-ray, computed tomography (CT) or magnetic resonance imaging (MRI). Therapy to treat liposarcoma largely

depends on the type, size and location of the tumor. Treatments for liposarcoma include: Surgery, Radiation therapy, and Chemotherapy. New therapies are under clinical trials assessment as a potential treatment for liposarcomas.

'Liposarcoma - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Liposarcoma pipeline landscape is provided which includes the disease overview and Liposarcoma treatment guidelines. The assessment part of the report embraces, in depth Liposarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Liposarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Liposarcoma R&D. The therapies under development are focused on novel approaches to treat/improve Liposarcoma.

Liposarcoma Emerging Drugs Chapters

This segment of the Liposarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Liposarcoma Emerging Drugs

RAIN-32: Rain Therapeutics

RAIN-32 (milademetan) is a small molecule based oral inhibitor of mouse double minute 2 (MDM2). MDM2 is a critical regulator of tumor protein 53 (p53), which is known as the “guardian of the genome”. RAIN-32 is in Phase III clinical studies for the treatment of Liposarcoma.

Selinexor: Karyopharm Therapeutics

Selinexor is a first-in-class selective inhibitor of nuclear transport (SINE) compound. The molecule functions by binding with, and inhibiting, the nuclear export protein, XPO1, leading to the accumulation of tumor suppressor proteins in the cell nucleus. Selinexor, with the brand name XPOVIO, has been approved by the USFDA for relapsed or refractory multiple myeloma, relapsed or refractory diffuse large B-cell lymphoma (DLBCL), and in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The drug is in Phase III clinical studies for the treatment of Liposarcoma.

Further product details are provided in the report.....

Liposarcoma: Therapeutic Assessment

This segment of the report provides insights about the different Liposarcoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Liposarcoma

There are approx. 15+ key companies which are developing the therapies for Liposarcoma. The companies which have their Liposarcoma drug candidates in the most advanced stage, i.e. Phase III include, Rain Therapeutics.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Liposarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Liposarcoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Liposarcoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Liposarcoma drugs.

Liposarcoma Report Insights

- Liposarcoma Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Liposarcoma Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Liposarcoma drugs?

How many Liposarcoma drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Liposarcoma?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Liposarcoma therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Liposarcoma and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Karyopharm Therapeutics

Rain Therapeutics

Pfizer

Sanofi

Incyte Corporation

Macrogenics

Adaptimmune

Merck KGaA

GlaxoSmithKline

Novartis Oncology

Immune Design

Syndivia

TerSera Therapeutics

Key Products

RAIN-32

PF-07220060

Selinexor

Cabazitaxel

Retifanlimab

Afamtresgene autoleucel

Avelumab

Letetresgene autoleucel

Ribociclib

LV 305

CMB 305

SDV-1101

Telotristat etiprate

Contents

- Introduction
- Executive Summary
- Liposarcoma: Overview
 - Causes
 - Mechanism of Action
 - Signs and Symptoms
 - Diagnosis
 - Disease Management
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Liposarcoma – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
 - Comparative Analysis
- RAIN-32: Rain Therapeutics
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Mid Stage Products (Phase II)
 - Comparative Analysis
- Cabazitaxel: Sanofi
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report
- Early Stage Products (Phase I/II)
 - Comparative Analysis
- Ribociclib: Novartis Oncology
 - Product Description
 - Research and Development

Product Development Activities
Drug profiles in the detailed report
Preclinical and Discovery Stage Products
 Comparative Analysis
SDV-1101: Syndivia
 Product Description
 Research and Development
 Product Development Activities
Drug profiles in the detailed report
Inactive Products
 Comparative Analysis
Liposarcoma Key Companies
Liposarcoma Key Products
Liposarcoma- Unmet Needs
Liposarcoma- Market Drivers and Barriers
Liposarcoma- Future Perspectives and Conclusion
Liposarcoma Analyst Views
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Liposarcoma
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Liposarcoma
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Liposarcoma - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/L8CD12402EFEN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/L8CD12402EFEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970